Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460199 | 0.82 | SIRT2 (0.62) | SIRT2MAPK10MAPK8SIRT1MAPK9 | |
| Anilinobenzamide SCHEMBL1318994 | 0.78 | SIRT2 (0.73) | SIRT2MAPK8SIRT1AURKA | |
| SCHEMBL17766595 | 0.78 | SIRT2 (0.56) | SIRT2MAPK10MAPK8SIRT1MAPK9 | |
| SCHEMBL10424663 | 0.77 | SIRT2 (0.62) | SIRT2SIRT1 | |
| SCHEMBL2154765 | 0.77 | PDCD1 (0.60) | SIRT2SIRT1 | |
| SCHEMBL10424288 | 0.73 | SIRT2 (0.74) | SIRT2MAPK10SIRT1MAPK9AURKA | |
| SCHEMBL10984674 | 0.73 | SIRT2 (0.69) | SIRT2SIRT1 | |
| SCHEMBL317825 | 0.73 | AURKA (0.65) | SIRT2MAPK10MAPK8SIRT1MAPK9 | |
| SCHEMBL5992131 | 0.72 | SIRT2 (0.67) | SIRT2SIRT1AURKA | |
| SCHEMBL2764148 | 0.72 | SIRT2 (0.67) | SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016086153-A2 | USE OF TETRAHYDRO!NDAZOLYLBEIMZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | ESANEX, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | SIRT2 1769/4885MAPK10 1634/4885MAPK8 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.